Jim Cramer's Mad Dash: B/E Aerospace Is Going Up, Up, UP!

NEW YORK (TheStreet) -- TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, called B/E Aerospace (BEAV) "one of my favorite stocks," on CNBC's "Cramer's Mad Dash" segment. 

The company is responsible for much of the interior work in both private and public jets. Due to the strong backlog for plane manufacturers, shares of BEAV have been "up, up, up!" he exclaimed. 

B/E Aerospace cancelled its analyst meeting originally scheduled for today, announcing that is exploring a potential sale, merger or split up, Cramer added.  Although some analysts are calling shares of BEAV overvalued, Cramer disagreed, arguing, "This company is worth a great deal." 

So who would buy the company? 

Rockwell Collins (COL) would be a possible merger candidate, he said, but not Honeywell International (HON). 

Turning to Pfizer (PFE), Cramer was not impressed by its earnings results. He added that AstraZeneca (AZN) -- the company Pfizer wants to buy -- does not have as strong a cancer pipeline as initially thought. 

He concluded that Merck (MRK) has a more "exciting story" than Pfizer, especially with its consumer products division.

-- Written by Bret Kenwell in Petoskey, Mich.

At the time of publication, Cramer's Action Alerts PLUS had no position in companies mentioned.

If you liked this article you might like

EU Expected to Approve Rockwell Collins Bid for B/E Aerospace

5 Things You Must Know Before the Market Opens Thursday

Here's Who Killed It in October Dealmaking Advice

Rockwell Collins Gambles on B/E at Top of Cycle

Jim Cramer's 'Mad Money' Recap: The Three Faces of the Stock Market